People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.
Esopredict, a test developed by Johns Hopkins Kimmel Cancer Center investigators, could give gastroenterologists insight into which patients with Barrett’s esophagus are likely to progress to esophageal cancer or an abnormal collection of cells called high-grade dysplasia, according to a recent study. This information could help physicians determine how to monitor or manage patients during clinical care.
Tumors with alterations in any of three specific genes were more likely than other tumors to be eliminated by cisplatin-based chemotherapy.
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.
Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.
Researchers at the Johns Hopkins Kimmel Cancer Center’s Sol Goldman Pancreatic Cancer Research Center have developed a 3D genomic profiling technique to identify small precancerous lesions in the pancreas—called pancreatic intraepithelial neoplasias—that lead to one of the most aggressive, deadly pancreatic cancers.
The American Association for Cancer Research named Nickolas Papadopoulos as editor-in-chief of Cancer Prevention Research, one 10 journals published by the AACR.
Working with human breast and lung cells, Johns Hopkins Medicine scientists say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells.
A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.
Chi Van Dang will receive the 2024 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research. The recognition will take place during this year’s AACR annual meeting, April 5-10 in San Diego, CA.
